Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH.

Background And Aim: Nonalcoholic fatty liver disease (NAFLD) affects about 25% of the global population, with no reliable noninvasive tests to diagnose nonalcoholic steatohepatitis (NASH) and to differentiate between NASH and nonalcoholic fatty liver (NAFL) (steatosis alone). It is unclear if NAFL and NASH differ in cardiovascular risk for patients. Here, we compared obese NAFLD patients with a healthy cohort to test whether cholesterol compounds could represent potential noninvasive markers and to estimate associated risks.

Modified test using a new test meal and a C-urea breath test in positive and negative dyspepsia patients on proton pump inhibitors.

Aim: To determine the sensitivity and specificity of the C-urea breath test (UBT) in patients taking proton pump inhibitors (PPIs), using a new test meal Refex.

Methods: One hundred and fourteen consecutive patients with dyspepsia, 53 () positive, 49 negative, were included in the study. The patients were then given esomeprazole 40 mg for 29 consecutive days, and the C-UBT with the new test meal was performed the next morning.

NMR-Based Screening for Inborn Errors of Metabolism: Initial Results from a Study on Turkish Neonates.

Approximately 1 in 400 neonates in Turkey is affected by inherited metabolic diseases. This high prevalence is at least in part due to consanguineous marriages. Standard screening in Turkey now covers only three metabolic diseases (phenylketonuria, congenital hypothyroidism, and biotinidase deficiency).